Moditen Depo (Fluphenazine Decanoate)

Fluphenazine decanoate blocks dopamine D2 receptors, reducing excessive dopaminergic activity that contributes to psychotic symptoms. The decanoate ester creates a depot effect, allowing slow, sustained release of the drug after a single injection, which maintains therapeutic levels over weeks.

The specific dose of Moditen Depo is determined by the prescribing clinician based on the patient’s clinical condition, prior response to therapy, and other individual factors. Dosage adjustments are made according to therapeutic response and tolerability.

Safety data for fluphenazine decanoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Moditen Depo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moditen Depo offers a long‑acting injectable formulation of a phenothiazine, providing extended coverage after a single dose, which can improve adherence compared with daily oral antipsychotics. Compared with newer atypical agents, it may have a higher propensity for extrapyramidal side effects but remains effective for patients who respond well to typical antipsychotics.

Moditen Depo should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Moditen Depo is administered by a healthcare professional via intravenous injection. The injection site and technique follow standard aseptic procedures, and the dosing interval is determined by the prescriber based on the patient’s clinical response.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, severe hypotension, agranulocytosis, seizures, and cardiac arrhythmias such as QT prolongation. Patients should be monitored closely for early signs of these conditions, and treatment should be discontinued if they occur.

Moditen Depo is contraindicated in patients with known hypersensitivity to fluphenazine, other phenothiazines, or any component of the formulation. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled epilepsy, or a history of neuroleptic malignant syndrome.